Dexamethasone prevents TACE-induced adverse events

Abstract

Background: While dexamethasone has been applied following transcatheter arterial chemoembolization (TACE) for years, its clinical effects have not been determined. In the current study, we aimed to evaluate the efficacy of dexamethasone in preventing adverse events induced by TACE. Methods: Literature retrieval was conducted using globally recognized online databases, namely MEDLINE, EMBASE, and Cochrane Central, to identify randomized controlled trials (RCTs) of dexamethasone application in patients undergoing TACE. The relative odds ratios (ORs) of incidence rates of three adverse events, namely, fever, abdominal pain and nausea/vomiting, were calculated. The value of I2 was applied to evaluate the heterogeneity of the trials, and the overall publication bias was assessed with Egger test. Results: Four RCTs containing 350 subjects were included for the pooled estimation. Dexamethasone significantly reduced the incidence rate of TACE-induced adverse events (OR = 1.237, 95% CI: 1.170–1.308, P < .001) with moderate heterogeneity (I2 = 46.0%). The result of Egger test revealed a publication bias for the included studies. Conclusion: The current meta-analysis confirmed the efficacy of dexamethasone in preventing TACE-induced adverse events. To confirm the practicality of dexamethasone use with TACE, further studies with large sample sizes are warranted to update the evidence-based analyses.

Efficacy and safety analysis of dexamethasone + palonosetron in prevention of post-embolization syndrome after D-TACE: A retrospective study

“…Especially for tumor patients, the resistance of the body decreases, and the risk of infection is higher. However, existing studies have shown that, [ 39 ] the use of dexamethasone in TACE does not increase the incidence of infection after TACE, and the use of dexamethasone in TACE is safe. The results of this study showed that the incidence of infection: D-TACE group versus D-TACE + dexamethasone + palonosetron group, 1.4% versus 1.5%, P = .931, there was no statistical difference, which was consistent with the results of other studies.…”

Efficacy and safety analysis of dexamethasone-lipiodol emulsion in prevention of post-embolization syndrome after TACE: a retrospective analysis

“…Since patients often feel good about themselves after using dexamethasone and mask the symptoms of infection development, the use of dexamethasone in TACE has the potential to increase the risk of infection in patients. However, existing studies [ 36 ] showed that the use of dexamethasone in the treatment of post-embolization syndrome after TACE did not increase the incidence of infection in patients, and the use of dexamethasone in TACE was safe. In this study, the incidence of infection after TACE: 2 cases in TACE group, with an incidence rate of 1.5%.…”

Innovative Invasive Loco-Regional Techniques for the Treatment of Lung Cancer

“…The observed AEs were nausea and vomiting (4.9%), dizziness (4.2%), abdominal pain (2.7%), abdominal distension (1.9%), allergy (1.1%) and renal function injury (1.14%). A meta-analysis, including four randomized clinical trials, revealed that dexamethasone administration significantly reduces the incidence rate of chemoembolization-related AEs [ 61 ].…”

“…Th. Vogl, T.J. [ 60 ] Clinical trial mets n/a CE 52 n/a Chang, L. [ 61 ] Meta-analysis N/S N/S CE CE 350 150 DEX n/a Jin, S.Q. [ 58 ] Clinical trial NSCLC IIA, IIIB, IV CE BAI 264 513 n/a n/a Boas, F.E.…”